• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

尿激酶型纤溶酶原激活系统基因多态性与非小细胞肺癌易感性和严重程度的关系。

Association of polymorphisms in the genes of the urokinase plasminogen activation system with susceptibility to and severity of non-small cell lung cancer.

机构信息

Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University Hospital, Taiwan, ROC.

出版信息

Clin Chim Acta. 2011 Jan 14;412(1-2):194-8. doi: 10.1016/j.cca.2010.10.004. Epub 2010 Oct 16.

DOI:10.1016/j.cca.2010.10.004
PMID:20937265
Abstract

BACKGROUND

Urokinase plasminogen activating (uPA) system is implicated in neoplastic progression. High tissue levels of uPA system components correlate with a poor prognosis in lung cancer. The present study examined the single nucleotide polymorphisms (SNPs) of uPA and the corresponding receptor, uPAR, for exploring their roles in non-small cell lung cancer (NSCLC).

METHODS

The allele frequencies and genotype distributions of uPA rs4065 C/T and uPAR rs344781 (-516 T/C) among 375 NSCLC cases and 380 healthy controls were examined using polymerase chain reaction-restriction fragment-length polymorphism (PCR-RFLP) analysis. Putative association between the above SNPs and clinicopathological characteristics of NSCLC were also analyzed.

RESULTS

The genotype frequencies of the variant homozygotes of uPA and uPAR were significantly different between NSCLC and control subjects. Significant association was also observed between the examined genotypes and disease stage of NSCLC. Logistic regression analysis revealed that individuals with uPA rs4065 TT genotype have higher odds ratios (ORs) for lung cancer. Whereas, subjects with uPAR-344781 CC genotype have lower ORs for lung cancer. The patients carrying a homozygous TT genotype at uPA rs4065, or at least a T allele at uPAR-344781 (-516), had a tendency to develop advanced disease.

CONCLUSIONS

Our results revealed that genetic polymorphisms of the uPA rs4065 C/T and uPAR rs344781 (-516 T/C) were associated with the susceptibility and severity of NSCLC.

摘要

背景

尿激酶型纤溶酶原激活物(uPA)系统参与肿瘤的进展。组织中 uPA 系统成分水平高与肺癌预后不良相关。本研究检测了 uPA 和相应受体 uPAR 的单核苷酸多态性(SNP),以探讨其在非小细胞肺癌(NSCLC)中的作用。

方法

采用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)分析,检测 375 例 NSCLC 病例和 380 例健康对照者 uPA rs4065 C/T 和 uPAR rs344781(-516 T/C)的等位基因频率和基因型分布。还分析了上述 SNP 与 NSCLC 临床病理特征的潜在关联。

结果

uPA 和 uPAR 变异纯合子的基因型频率在 NSCLC 和对照组之间存在显著差异。所研究的基因型与 NSCLC 的疾病分期也存在显著相关性。Logistic 回归分析显示,uPA rs4065 TT 基因型个体患肺癌的比值比(OR)更高。而 uPAR-344781 CC 基因型个体患肺癌的 OR 较低。uPA rs4065 处 TT 基因型纯合子或 uPAR-344781(-516)处至少存在 T 等位基因的患者,有发展为晚期疾病的趋势。

结论

我们的研究结果表明,uPA rs4065 C/T 和 uPAR rs344781(-516 T/C)的遗传多态性与 NSCLC 的易感性和严重程度相关。

相似文献

1
Association of polymorphisms in the genes of the urokinase plasminogen activation system with susceptibility to and severity of non-small cell lung cancer.尿激酶型纤溶酶原激活系统基因多态性与非小细胞肺癌易感性和严重程度的关系。
Clin Chim Acta. 2011 Jan 14;412(1-2):194-8. doi: 10.1016/j.cca.2010.10.004. Epub 2010 Oct 16.
2
The circulating urokinase plasminogen activator (uPA) and its soluble receptor (suPAR) are not up-regulated by the circulating P105 fraction of the HER-2/neu proto-oncogene: in vivo evidence from patients with advanced non-small cell lung cancer (NSCLC).循环尿激酶型纤溶酶原激活剂(uPA)及其可溶性受体(suPAR)不会被HER-2/neu原癌基因的循环P105片段上调:来自晚期非小细胞肺癌(NSCLC)患者的体内证据。
Anticancer Res. 2002 Jul-Aug;22(4):2073-6.
3
[Influence of overexpressed coagulant and fibrolytic components in tumor tissues on the prognosis of non-small cell lung cancer].[肿瘤组织中凝血和纤溶成分过表达对非小细胞肺癌预后的影响]
Zhonghua Yi Xue Za Zhi. 2007 Dec 4;87(45):3228-32.
4
Evaluation of the association of urokinase plasminogen activator system gene polymorphisms with susceptibility and pathological development of hepatocellular carcinoma.评价尿激酶纤溶酶原激活系统基因多态性与肝细胞癌易感性及病理发展的关系。
Ann Surg Oncol. 2010 Dec;17(12):3394-401. doi: 10.1245/s10434-010-1124-y. Epub 2010 Aug 13.
5
Changes in plasminogen activator inhibitor-1 levels in non-small cell lung cancer.非小细胞肺癌中纤溶酶原激活物抑制剂-1水平的变化
Boll Soc Ital Biol Sper. 1996 Nov-Dec;72(11-12):331-40.
6
Plasminogen activator inhibitor variants PAI-1 A15T and PAI-2 S413C influence lung cancer prognosis.纤溶酶原激活物抑制剂变体PAI-1 A15T和PAI-2 S413C影响肺癌预后。
Lung Cancer. 2009 Aug;65(2):237-41. doi: 10.1016/j.lungcan.2008.11.012. Epub 2008 Dec 31.
7
Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.尿激酶、尿激酶受体及1型纤溶酶原激活物抑制剂在肺鳞状细胞癌和大细胞癌组织中的预后影响
Cancer Res. 1994 Sep 1;54(17):4671-5.
8
The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.乳腺肿瘤组织基质中的尿激酶系统与乳腺癌细胞侵袭
Int J Oncol. 2009 Jan;34(1):15-23.
9
Impact of uPA system gene polymorphisms on the susceptibility of environmental factors to carcinogenesis and the development of clinicopathology of oral cancer.尿激酶型纤溶酶原激活物系统基因多态性对环境因素致癌易感性及口腔癌临床病理发展的影响。
Ann Surg Oncol. 2011 Mar;18(3):805-12. doi: 10.1245/s10434-010-1432-2. Epub 2010 Dec 2.
10
Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis.非小细胞肺癌中尿激酶型纤溶酶原激活物和1型纤溶酶原激活物抑制剂:与预后和血管生成的关系
Lung Cancer. 2007 Apr;56(1):43-50. doi: 10.1016/j.lungcan.2006.11.018. Epub 2007 Jan 17.

引用本文的文献

1
Proteolysis is the most fundamental property of malignancy and its inhibition may be used therapeutically (Review).蛋白水解作用是恶性肿瘤最基本的特性,其抑制作用可能具有治疗用途(综述)。
Int J Mol Med. 2019 Jan;43(1):15-25. doi: 10.3892/ijmm.2018.3983. Epub 2018 Nov 7.
2
The study of the relation of DNA repair pathway genes SNPs and the sensitivity to radiotherapy and chemotherapy of NSCLC.DNA 修复通路基因单核苷酸多态性与 NSCLC 放疗和化疗敏感性关系的研究。
Sci Rep. 2016 Jun 1;6:26526. doi: 10.1038/srep26526.
3
Association between the polymorphisms of urokinase plasminogen activation system and cancer risk: a meta-analysis.
尿激酶纤溶酶原激活系统多态性与癌症风险的关联:荟萃分析。
Onco Targets Ther. 2015 Sep 9;8:2493-502. doi: 10.2147/OTT.S85520. eCollection 2015.
4
Meta-analysis of the urokinase gene 3'-UTR T/C polymorphism and susceptibility to urolithiasis.尿激酶基因3'-UTR T/C多态性与尿石症易感性的Meta分析。
Biomed Rep. 2013 May;1(3):369-374. doi: 10.3892/br.2013.73. Epub 2013 Mar 7.
5
Intracerebral infusion of the bispecific targeted toxin DTATEGF in a mouse xenograft model of a human metastatic non-small cell lung cancer.脑内输注双特异性靶向毒素 DTATEGF 于人转移性非小细胞肺癌异种移植模型中。
J Neurooncol. 2012 Sep;109(2):229-38. doi: 10.1007/s11060-012-0904-6. Epub 2012 Jun 14.